Departed
James Young
Chief Financial Officer
TLSI ·
TriSalus Life Sciences, Inc.
Mr. Young resigned from the Company for personal reasons, effective May 30, 2025.
TLSI
TriSalus Life Sciences, Inc.
Saved in this browser
Ready 8-Ks
16
Latest filing
May 14, 2026 20:03 UTC
Top materiality
0.75
Event mix
leadership ×6 · other_material ×5 · earnings ×5
Sentiment
3 pos · 1 neg · 12 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for TLSI
Highest-materiality recent filing
TriSalus Q1 revenue $8.9M (-2.9% YoY); revises FY 2026 guidance to $54-57M
- Revenue $8.9M, down 2.9% YoY; gross margin improved to 86.2% from 83.7%.
- Net income $1.5M ($0.03 EPS) on $11.3M non-cash derivative gains; adj. EBITDA loss $5.8M.
-
TriSalus annual meeting elects two directors, ratifies auditor, approves say-on-pay frequency
Mary Szela and Gary Gordon elected to three-year director terms with ~92% for votes.
-
TriSalus Q1 revenue $8.9M (-2.9% YoY); revises FY 2026 guidance to $54-57M
Revenue $8.9M, down 2.9% YoY; gross margin improved to 86.2% from 83.7%.
-
TriSalus Life Sciences Chief of Clinical Operations Jodi Devlin to retire October 1, 2026
Jodi Devlin notified Company on April 24, 2026 of retirement as Chief of Clinical Operations.
-
TriSalus appoints Dr. Richard Marshall as CMO, effective June 29, 2026
Annual base salary of $525,000; sign-on bonus of $250,000.
-
TriSalus Q4 revenue $13.2M (+60% YoY); reaffirms 2026 revenue guidance $60-62M
Full-year 2025 revenue $45.2M (+53% YoY); Q4 gross margin 86.7% vs 85.3% prior year.
-
TriSalus prices $40M public offering of 9.76M shares at $4.10/share
Gross proceeds ~$40.0M from 9,756,100 shares at $4.10/share; net proceeds ~$37.0M (before over-allotment).
-
TriSalus Life Sciences appoints Michael Stansky to board, replacing Dr. Desai
Dr. Arjun "JJ" Desai resigned from the board on February 3, 2026; no disagreement with the company.
-
TriSalus reports Q4 revenue $13.2M (+60% YoY), FY25 $45.2M (+53%), FY26 guidance $60-62M
Q4 2025 revenue approx $13.2M vs $8.3M year ago, up 60% YoY; full-year revenue approx $45.2M vs $29.4M, up 53% YoY.
-
Revenue $11.6M, up 57% YoY and 3% sequentially; all from TriNav liver embolization.
-
TriSalus director Sean Murphy resigns from Board and Science Committee
Sean Murphy resigned from the Board and the Science and Technology Committee effective September 30, 2025.
-
TriSalus Life Sciences raises CFO base salary to $550K, grants performance-based stock options
CFO David Patience's annual base salary increased from $450K to $550K, effective immediately.
-
TriSalus Q2 revenue $11.2M (+52% YoY); reaffirms 50% FY growth; net loss $9.0M
Revenue $11.2M, +52% YoY, +22% sequential; gross margin 84% vs 88%.
-
TriSalus completes Preferred Stock exchange; 98.82% tendered at 3.3 common shares each
Approximately 98.82% of outstanding Series A Convertible Preferred Stock (3,551,502 shares) validly tendered in exchange offer.
-
TriSalus launches exchange offer for Series A Preferred, up to 11.9M common shares
Offers up to 11,860,206 common shares in exchange for each share of Series A Convertible Preferred at $4.00 per share based on liquidation preference plus accrued dividends through Aug 10, 2027.
-
TriSalus shareholders elect Wahlström and Matlin to board, ratify Grant Thornton
Mats Wahlström and David J. Matlin elected to three-year terms with 20,002,109 and 20,005,151 votes for, respectively; 5,978,753 broker non-votes each.
-
TriSalus Life Sciences appoints David Patience as CFO; James Young resigns
CFO James Young resigned for personal reasons effective May 30, 2025; receives six months salary and continued equity vesting through May 2026.
Executive changes
Appointed
David Patience
Chief Financial Officer
TLSI ·
TriSalus Life Sciences, Inc.
On May 27, 2025, the Company entered into an offer letter with David Patience for the position of Chief Financial Officer.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.75 · Median 0.60 · Most common event leadership